Invibio has launched its new corporate identity, with a focus on materials, manufacturing and knowledge. In conjunction with the new identity, Invibio has launched a new website, which is now live at invibio.com.
Invibio Launches New Corporate Identity
1 min read Premium comments
Secondary
Their tagline is: “Materials. Manufacturing. Knowledge.” This demonstrates: Materials: provision of the PEEK-OPTIMA family of implantable polymers and innovative new product grades and forms, manufacturing of customers medical device components combined with extensive scientific, regulatory and application knowledge and expertise.
Invibio Managing Director Martin Court explained in the November 22, 2013 news release, “Our customers choose Invibio because our investment in innovation and transfer of knowledge helps them to more easily achieve their growth and innovation goals, it’s a true partnership that benefits both parties.” Court continues, “The enhanced Invibio brand marks a significant and exciting time for us at Invibio. The branding and structure of how we communicate now accurately represents our unique position in the industry with a distinct identity and a strong, visible brand that encompasses the total value we provide to our clients.”
Asked about why it was a good time to develop the new corporate identity, Court told OTW, “It wasn’t! In reality we’ve broadened our offering to medical device companies extensively in recent years and our brand is finally catching up. The medical device industry has a number of significant challenges at the moment and our approach to establishing clinical benefits, increasing manufacturing efficiency and accelerating market entry and reach will address these challenges.”
As for how things will look different in a year, Court told OTW, “There will be real evidence of our progress. We’ve just launched our PEEK-OPTIMA HA Enhanced product to enhance bone apposition in spinal fusion and will also launch our trauma plate manufacturing capability in the forthcoming year. These are just two examples of listening to surgeon’s needs, collaborating with leading research institutes to provide evidence that we can address these needs and launching safe reliable materials and device components to meet demand.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.